{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:28:08Z","timestamp":1792794488662,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Biocon Biologics UK Limited"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This randomized, double-blind, multicenter Phase 3 trial evaluated the efficacy, safety, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of Bmab 1000 vs reference denosumab in 479 women with postmenopausal osteoporosis. Participants (mean age 66.6\u00a0yr; lumbar spine T-score \u2264\u22122.5 to \u2265\u22124.0) were randomized 1:1 to receive 60\u00a0mg Bmab 1000 (n\u2009=\u2009238) or reference denosumab (n\u2009=\u2009241) subcutaneously. The study comprised 2 parts: Part 1 (weeks 0-52) evaluated therapeutic and PD equivalence between Bmab 1000 and reference denosumab using percentage change from baseline (%CfB) in lumbar spine bone mineral density (BMD) at week 52 and area under the effect curve (AUEC) of serum C-terminal telopeptide of Type 1 collagen (sCTX) from baseline to 26\u00a0wk following dosing on day 1 and week 26. Part 2 (weeks 52-78) re-randomized those on reference denosumab to either continue or switch to Bmab 1000 (n\u2009=\u2009104 each), while those on Bmab 1000 continued treatment (n\u2009=\u2009218). Part 2 monitored the safety of Bmab 1000 and reference denosumab after transition from reference denosumab to Bmab 1000 vs continuing reference denosumab. Secondary analyses included additional efficacy, PD, PK, safety, and immunogenicity parameters. At week 52, the confidence intervals (CIs) for the difference in least square means (LSMs) in %CfB in lumbar spine BMD between Bmab 1000 and reference denosumab were contained within the predefined margins (\u00b11.45; LSM diff: 0.610, 95% CI: \u22120.095, 1.316), indicating therapeutic equivalence. The sCTX AUEC up to 26\u00a0wk for Bmab 1000 and reference denosumab were similar (geometric LSM ratio: 104.14; 95% CI: 97.76, 110.95). The secondary results were comparable among all groups up to week 78, including after transitioning to Bmab 1000 from reference denosumab. In conclusion, Bmab 1000 demonstrated equivalent efficacy and PD to reference denosumab, with similar PK, safety, and immunogenicity profiles. There was no effect of transitioning from reference denosumab to Bmab 1000.<\/jats:p>\n                  <jats:p>Clinical trial registration: EudraCT number: 2021-006545-36, CT.gov number: NCT05345691.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziag062","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:42:55Z","timestamp":1775734975000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-3366","authenticated-orcid":false,"given":"Richard","family":"Eastell","sequence":"first","affiliation":[{"name":"Division of Clinical Medicine, University of Sheffield , Sheffield S10 2RX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-7355","authenticated-orcid":false,"given":"Eric","family":"Orwoll","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Oregon Health and Science University , Portland, OR 97239 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-6616","authenticated-orcid":false,"given":"Felicia","family":"Cosman","sequence":"additional","affiliation":[{"name":"Regional Bone and Clinical Research Centers, Helen Hayes Hospital , West Haverstraw, NY 10993 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Plebanski","sequence":"additional","affiliation":[{"name":"Department of Clinic of Healthy Bone, Klinika Zdrowej Kosci , 91-843 Lodz ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Clinical Development and Medical Affairs, Biocon Biologics Limited , Bengaluru 560100 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Marwah","sequence":"additional","affiliation":[{"name":"Clinical Development and Medical Affairs, Biocon Biologics Limited , Bengaluru 560100 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-8505","authenticated-orcid":false,"given":"Sarika S","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Clinical Development and Medical Affairs, Biocon Biologics Limited , Bengaluru 560100 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Wolff-Holz","sequence":"additional","affiliation":[{"name":"Clinical Development and Medical Affairs, Biocon Biologics UK Limited , London WC2B 5AH ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Loganathan","sequence":"additional","affiliation":[{"name":"Clinical Development and Medical Affairs, Biocon Biologics Limited , Bengaluru 560100 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"8","key":"2026052822571302500_ref1","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14712598.2025.2540471","article-title":"Biosimilars in osteoporosis treatment: focus on denosumab","volume":"25","author":"Aapro","year":"2025","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2026052822571302500_ref2","doi-asserted-by":"publisher","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"2026052822571302500_ref3","volume-title":"Epidemiology of Osteoporosis and Fragility Fractures","author":"IOF","year":"2025"},{"issue":"5","key":"2026052822571302500_ref4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/pl00004148","article-title":"World-wide projections for hip fracture","volume":"7","author":"Gullberg","year":"1997","journal-title":"Osteoporos Int"},{"issue":"3","key":"2026052822571302500_ref5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Guideline Update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026052822571302500_ref6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"10329","key":"2026052822571302500_ref7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"2026052822571302500_ref8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1186\/s13018-025-06084-5","article-title":"Short-term anabolic agent and sequential therapy to improve bone mineral density and bone turnover markers in patients with osteoporotic hip fractures","volume":"20","author":"Park","year":"2025","journal-title":"J Orthop Surg Res"},{"issue":"Suppl 1","key":"2026052822571302500_ref9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s43465-023-01067-2","article-title":"The sequential therapy in osteoporosis","volume":"57","author":"Sauhta","year":"2023","journal-title":"Indian J Orthop"},{"issue":"04","key":"2026052822571302500_ref10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4103\/2278-330X.119895","article-title":"Denosumab: a comprehensive review","volume":"02","author":"Narayanan","year":"2013","journal-title":"South Asian J Cancer"},{"key":"2026052822571302500_ref11","author":"FDA"},{"key":"2026052822571302500_ref12","author":"EMA"},{"issue":"8","key":"2026052822571302500_ref13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2026052822571302500_ref14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026052822571302500_ref15","volume-title":"FDA Adds Boxed Warning for Increased Risk of Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease Taking Osteoporosis Medicine Prolia (Denosumab)","author":"Food and Drug Administration (FDA)","year":"2024"},{"key":"2026052822571302500_ref16","volume-title":"Denosumab","author":"NCI"},{"key":"2026052822571302500_ref17","author":"FDA"},{"key":"2026052822571302500_ref18","author":"EMA"},{"key":"2026052822571302500_ref19","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2026052822571302500_ref20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000496834","article-title":"What does the pipeline promise about upcoming biosimilar antibodies in oncology?","volume":"14","author":"Busse","year":"2019","journal-title":"Breast Care"},{"key":"2026052822571302500_ref21","doi-asserted-by":"publisher","first-page":"104467","DOI":"10.1016\/j.phrs.2019.104467","article-title":"Biosimilars in rheumatology","volume":"149","author":"Ara\u00fajo","year":"2019","journal-title":"Pharmacol Res"},{"issue":"3","key":"2026052822571302500_ref22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/jbmr\/zjae016","article-title":"Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study","volume":"39","author":"Jeka","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026052822571302500_ref23","doi-asserted-by":"publisher","first-page":"e1951","DOI":"10.1210\/clinem\/dgae611","article-title":"Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis: phase 3 results up to month 12","volume":"110","author":"Langdahl","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026052822571302500_ref24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13075-022-02840-8","article-title":"Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia\u00ae) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial","volume":"24","author":"Jamshidi","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2026052822571302500_ref25","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.59556\/japi.73.0772","article-title":"A prospective, active-controlled, randomized, double-blind, multicenter, phase III study to compare the safety and efficacy of biosimilar denosumab vs reference denosumab in the treatment of postmenopausal osteoporosis","volume":"73","author":"Paul","year":"2025","journal-title":"J Assoc Physicians India"},{"issue":"8","key":"2026052822571302500_ref26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/14712598.2025.2538609","article-title":"A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosis","volume":"25","author":"Lortkipanidze","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"2026052822571302500_ref27","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00198-024-07161-x","article-title":"Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, phase 3 trial in postmenopausal women with osteoporosis","volume":"35","author":"Reginster","year":"2024","journal-title":"Osteoporos Int"},{"key":"2026052822571302500_ref28","doi-asserted-by":"publisher","first-page":"117371","DOI":"10.1016\/j.bone.2024.117371","article-title":"SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial","volume":"192","author":"Chung","year":"2025","journal-title":"Bone"},{"issue":"4","key":"2026052822571302500_ref29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.11005\/jbm.2022.29.4.217","article-title":"The role of bisphosphonates prior to denosumab treatment on rebound fractures: a mini review","volume":"29","author":"Inojosa","year":"2022","journal-title":"J Bone Metab"},{"issue":"11","key":"2026052822571302500_ref30","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziag062\/68032731\/ziag062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/6\/ziag062\/68032731\/ziag062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/6\/ziag062\/68032731\/ziag062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:57:36Z","timestamp":1780023456000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziag062\/8651590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziag062","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,11]]},"article-number":"ziag062"}}